Biodexa Pharmaceuticals (BDRX) News Today $3.85 +0.23 (+6.35%) (As of 09:17 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Biodexa Pharmaceuticals Secures Nasdaq Listing ComplianceNovember 13, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals regains Nasdaq complianceNovember 13, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on NasdaqNovember 12, 2024 | globenewswire.comBiodexa Pharmaceuticals Plans Strategic Share Value AdjustmentNovember 9, 2024 | markets.businessinsider.comNotice of General MeetingNovember 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXNovember 2, 2024 | prnewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 29, 2024 | globenewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 28, 2024 | businesswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXOctober 25, 2024 | prnewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 23, 2024 | globenewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 20, 2024 | businesswire.comBiodexa ADRs Rise After Successful Appeal of Nasdaq DelistingOctober 17, 2024 | marketwatch.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXOctober 17, 2024 | prnewswire.comLost Money on Biodexa Pharmaceuticals Plc (BDRX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationOctober 16, 2024 | stockhouse.comBiodexa Pharmaceuticals PLC: Biodexa Announces Successful Appeal of Nasdaq DelistingOctober 16, 2024 | finanznachrichten.deBiodexa Pharmaceuticals Stock Is Soaring After The Close: What's Driving Shares Higher?October 16, 2024 | benzinga.comBiodexa Announces Successful Appeal of Nasdaq DelistingOctober 15, 2024 | globenewswire.comFreightCar America (NASDAQ:RAIL) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comBiodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comBiodexa reports survival rates in glioblastoma studyOctober 6, 2024 | uk.investing.comBiodexa reports updated Phase 1 data from glioblastoma studyOctober 4, 2024 | msn.comBiodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaOctober 4, 2024 | globenewswire.comInterim results for the six months ended June 30, 2024September 26, 2024 | globenewswire.comADR Ratio ChangeSeptember 19, 2024 | globenewswire.comBiodexa secures full access to cancer research grantSeptember 18, 2024 | uk.investing.comAnnounces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantSeptember 16, 2024 | finance.yahoo.comReceipt of Nasdaq Delisting Determination - Plans to AppealAugust 30, 2024 | globenewswire.comBiodexa Pharmaceuticals files for 4.35B ordinary shares for holdersAugust 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Flat in Monday TradingAugust 12, 2024 | msn.comAnnounces Closing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementJuly 23, 2024 | globenewswire.comAnnounces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementJuly 19, 2024 | globenewswire.comWhy Is Biodexa Pharmaceuticals (BDRX) Up 56% Today?July 11, 2024 | investorplace.comPositive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024July 2, 2024 | globenewswire.comBiodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)June 24, 2024 | globenewswire.comResults of Annual General MeetingJune 13, 2024 | globenewswire.comTwelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in BarcelonaJune 10, 2024 | globenewswire.comBiodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?May 22, 2024 | msn.comGold Moves Lower; Macy's Boosts 2024 ForecastMay 22, 2024 | msn.comBiodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesMay 22, 2024 | globenewswire.comWhat's Going On With Biodexa Pharmaceuticals Stock?May 21, 2024 | msn.comBiodexa rallies 80% on positive Phase 2 data for eRapaMay 21, 2024 | msn.comPositive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual MeetingMay 21, 2024 | finance.yahoo.comPositive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual MeetingMay 21, 2024 | globenewswire.comWhy Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today?May 21, 2024 | investorplace.comPosting of Annual Report & Notice of AGM - Total Voting RightsMay 15, 2024 | finance.yahoo.comBiodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingApril 30, 2024 | finance.yahoo.comBiodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingApril 30, 2024 | globenewswire.comBiodexa shares rally 126% on rapamycin licensing dealApril 26, 2024 | seekingalpha.comWhy Is Biodexa (BDRX) Up 70% Today?April 26, 2024 | investorplace.com Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now BDRX Media Mentions By Week BDRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDRX News Sentiment▼0.440.56▲Average Medical News Sentiment BDRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDRX Articles This Week▼51▲BDRX Articles Average Week Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PaxMedica News Today Qualigen Therapeutics News Today Cyclacel Pharmaceuticals News Today TC Biopharm News Today Elevai Labs News Today PainReform News Today NexImmune News Today Seelos Therapeutics News Today TRACON Pharmaceuticals News Today Navidea Biopharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDRX) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredTrump Win = "Bull Trap"?Dan's research shows that the last time the market looked this way, not only did our economy suffer a large su...Stansberry Research | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDRX Stock Alerts